Tovorafenib (Ojemda)

From - A Hematology Oncology Wiki
Jump to navigation Jump to search

Mechanism of action

From the NCI Drug Dictionary: An orally available inhibitor of wild-type and certain mutant forms of A-Raf, B-Raf and C-Raf protein kinases, with potential antineoplastic activity. Upon administration, tovorafenib inhibits Raf-mediated signal transduction pathways, which may lead to an inhibition of tumor cell growth.

Diseases for which it is used

History of changes in FDA indication

  • 2024-04-23: Granted accelerated approval to tovorafenib (Ojemda, Day One Biopharmaceuticals, Inc.) for patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. (Based on FIREFLY-1)

Also known as

  • Code names: BIIB-024, DAY-101, MLN-2480, TAK-580
  • Brand name: Ojemda